Syndax Pharmaceuticals (SNDX) News Today

Candriam S.C.A. decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 970,106 shares of the company's stock after

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.4%

Panagora Asset Management Inc. cut its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 65.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,849 shares of the company's stock after selling 154,157 shares during the peri

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating

SG Americas Securities LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,051 shares of the

Assenagon Asset Management S.A. lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 54.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 428,949 shares

Citigroup upped their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research note on Friday.

Bank of America boosted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday.

Vanguard Group Inc. raised its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 13.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,926,984 shares of the company's stock after buy

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same period in the previous year, the business posted ($0.64) EPS. The firm's revenue was up 3499999990.0% on a year-over-year basis.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Syndax Pharmaceuticals in a research report issued on Monday, July 29th. HC Wainwright analyst E. White now anticipates that the company will post

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company.

HC Wainwright reaffirmed a "buy" rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday.

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down to $24.49

Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.

BNP Paribas Financial Markets lowered its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 72.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,602 shares of the company's stock after sel

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 109,827 shares of the

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 8,340,000 shares, a drop of 15.9% from the June 15th total of 9,920,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 8.1 days.

Nvwm LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,962 shares of the company's stock, valued at approxi

Vanguard Group Inc. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,335,353 shares of the

Principal Financial Group Inc. cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 65.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,829 shares of the company's stock after selling

Jefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $37.00 price objective for the company.

Stifel Nicolaus increased their target price on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday.

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.1%